Erasca, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational drug, ERAS-0015, for the treatment of metastatic pancreatic adenoc

Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an ​early-stage trial of its experimental cancer drug, even though ‌analysts said the incident was unlikely to signal a broader safety issue.

Investors in Erasca, Inc. with financial losses may now have the opportunity to lead a class action lawsuit regarding securities fraud, following serious allegations.

Erasca, Inc. investors are being alerted to a securities fraud lawsuit opportunity by the Rosen Law Firm, emphasizing the importance of timely action.

Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026. The Fly reported on May 4 that JPMorgan is maintaining an

Erasca, Inc. is embroiled in a class action lawsuit for allegedly providing misleading information to investors. The DJS Law Group is seeking shareholder participation.

Erasca Inc. is facing legal actions as its stock plunges significantly. Allegations of patent infringement and patient safety concerns pose serious challenges to the company.

Form 144 filed for Erasca on Apr 1, 2026; Rule 144 requires filing for sales >5,000 shares or $50,000 and limits affiliates to 1% of outstanding shares or 4-week avg vol.

Erasca targets $550M offering; Summit sells ridinilazole; FDA approves at-home subcutaneous Leqembi; WuXi AppTec update; and Q32 Bio plans $200M offering.

New pan-KRAS inhibitor targets multiple mutations while sparing HRAS/NRAS. Phase 1 BOREALIS-1 trial to begin for solid tumors. See full development timeline.

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve...

Erasca (ERAS) will present updated monotherapy clinical data for ERAS-0015 from the ongoing Phase 1 AURORAS-1 trial and nonclinical combination data for ERAS-0015 plus ERAS-4001 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held November 18-20 in Barcelona, Spain.The oral presentation will cover preliminary safety, pharmacokinetics, and efficacy results of ERAS-0015 in its first-in-human trial. A poster will detail nonclinical data showing that combining ERAS-0015, a potential best-in-class pan-RAS molecular glue, with ERAS-4001, a potential first- and best-in-class pan-KRAS inhibitor, targets active and inactive KRAS and demonstrates synergy in KRAS G12X-driven models.

Erasca (ERAS) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. Management is scheduled for a fireside chat on Tuesday, September 15, 2026, at 1:05 p.m. Eastern Time and will hold one-on-one investor meetings. A live audio webcast and a 30-day archived replay will be accessible at Erasca.com/events.

Reported Thursday, Aug 27 - 9:08am EDT (TheFly subscription required to read more.)

Erasca's ERAS-0015 has received Fast Track Designation for metastatic pancreatic adenocarcinoma, backed by a 57% response rate in second-line KRAS-mutant patients.

Erasca (Nasdaq: ERAS) announced that the U.S. Food and Drug Administration granted Fast Track Designation (FTD) to its oral pan-RAS molecular glue ERAS-0015 for treating patients with metastatic pancreatic adenocarcinoma. ERAS-0015 is designed to inhibit RAS signaling and is being evaluated for a potential best-in-class profile.According to Erasca, FTD, which supports development of therapies for serious conditions with unmet needs, may provide more frequent FDA interactions and potential eligibility for accelerated approval, priority review, and rolling review. The designation follows preliminary Phase 1 AURORAS-1 data in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, where ERAS-0015 monotherapy at the 32 mg once-daily recommended dose for expansion showed a 57% uORR8wk, with all responding patients across doses remaining on treatment at the May 25, 2026 cutoff and a favorable tolerability profile. Erasca plans three potentially registration-enabling trials across pancreatic and lung cancers and expects additional monotherapy and combination data, including with panitumumab, in the first half of 2027.